Black Rock Inc. Zymeworks Inc. Transaction History

Black Rock Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$4.65 - $7.43 $12,978 - $20,737	-2,791 Reduced 0.48%	581,709 $3.58 Million
Q2 2022 Aug 12, 2022	SELL	$4.82 - $7.7 $1.87 Million - $2.99 Million	-388,951 Reduced 39.96%	584,500 $3.1 Million
Q1 2022 May 12, 2022	BUY	$6.0 - $16.98 $974,118 - $2.76 Million	162,353 Added 20.02%	973,451 $6.38 Million
Q4 2021 Feb 10, 2022	BUY	$15.19 - $29.33 $498,216 - $961,994	32,799 Added 4.21%	811,098 $13.3 Million
Q3 2021 Nov 09, 2021	SELL	$27.35 - $37.28 $5.29 Million - $7.21 Million	-193,434 Reduced 19.91%	778,299 $22.6 Million
Q2 2021 Aug 11, 2021	BUY	$26.5 - $38.23 $25.8 Million - $37.1 Million	971,733 New	971,733 $33.7 Million

296K

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $901M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.